Skip to main content

Incyte

Incyte Corporation is an American biopharmaceutical company focused on the discovery, development, and commercialization of proprietary therapeutics. The company operates mainly in the hematology, oncology, and inflammation and autoimmunity therapeutic areas. Its primary commercial product is ruxolitinib, marketed under the trade names Jakafi and Opzelura for myelofibrosis and dermatological conditions. Revenue is driven predominantly by product sales of its key therapeutic drugs alongside royalty streams and licensing milestones from global partners. Incyte maintains a strong market position in target-specific oncology and small molecule inhibitor research. The company is headquartered in Wilmington, Delaware, and is listed on the Nasdaq Global Select Market.

43 of the funds FundTelligence covers report a position in Incyte.

Legal name
Incyte Corp
Sector
Health Care
Country
United States
Funds holding it
43

Funds holding Incyte

Showing the 8 largest of 43 funds holding it.

Loading...